 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 The researchers also found that the sooner patients get into treatment, the better.
"Treatment success is highly dependent on starting before liver cirrhosis has already set in, which can take from a year to decades," Sulkowski noted in the news release.
Evidence from the study also will help doctors learn more quickly whether the patient is responding to the drug therapy. This will allow patients to avoid side effects and the expense of taking unnecessary drugs.
Text Continues Below
The study was funded by the Schering-Plough Corp., the maker and provider of the study drugs ribavirin and peginterferon alfa-b.
More information
The U.S. Centers for Disease Control and Prevention has more information on hepatitis.
Page: << Prev | 1 | 2
-- Dennis Thompson
|
.gif)
